Anson Funds Management’s Mustang Bio MBIO Stock Holding History

Anson Funds Management’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-45,716	Closed	-$57.1K	–	134
2025 Q1	$57.1K	Buy	+45,716	New	+$174K	0.01%	113

Other funds holding MBIO

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Anson Funds Management's MBIO Position: Q2 2025 in Review

Anson Funds Management sold out of Mustang Bio (MBIO) in Q2 2025, closing a stake of 45,716 shares — an estimated $57.1K sold.

Anson Funds Management first reported a position in MBIO in Q1 2025 and held it in 1 quarter. The position peaked at $57.1K in Q1 2025. 17 funds tracked by Wall St. Rank hold MBIO as of Q2 2025.

Anson Funds Management reported no remaining Mustang Bio position as of Q2 2025 after selling out during the quarter.
Anson Funds Management sold 45,716 Mustang Bio shares in Q2 2025, an estimated $57.1K.
Anson Funds Management first reported a position in Mustang Bio in Q1 2025 and held it in 1 quarter.
Anson Funds Management's Mustang Bio position peaked at $57.1K in Q1 2025.
17 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2025.

Based on Anson Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.